BRIEF-IP Says P2b Study Of Leramistat In RA Did Not Meet Primary Endpoint

Feb 17 (Reuters) - IP Group PLC IPO.L:

• ISTESSO UPDATE ON P2B STUDY OF LERAMISTAT IN RA

• STUDY DID NOT MEET PRIMARY ENDPOINT OF IMPROVEMENT IN ACR20 VERSUS PLACEBO

• SIGNIFICANT IMPROVEMENTS WERE SEEN IN KEY SECONDARY ENDPOINT

• NO NEW SAFETY CONCERNS WERE IDENTIFIED IN STUDY

Source text: ID:nRSQ3274Xa

Further company coverage: IPO.L